Dyne Therapeutics, Inc.
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
No enriched coverage for $DYN in the last 7 days.
Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.
Posner Brian S purchased 2,500 shares of Dyne Therapeutics, Inc. (DYN) at $16.00 on 2026-10-02.
Dyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o
Recent DYN coverage spans market movers, technology and financial news.
In the last 30 days, DYN insiders filed 1 SEC Form 4 transaction — 1 purchase ($40K) and no sales. The most active reporter was Posner Brian S with 1 filing.
Positive trial data may lift the stock as investors reassess the pipeline.
Small insider purchase may signal confidence but limited market impact.
Positive trial data suggest potential accelerated approval, likely supporting the stock.
Positive efficacy data may lift DYN stock as investors anticipate regulatory filing.
Short-term price pressure as investors take profits.
AlphAI scores every news story that mentions DYN with an AI model for sentiment and relevance, and aggregates insider trades from Dyne Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Dyne Therapeutics (DYN) reported 1-year efficacy and safety data from its Phase 1/2 ACHIEVE trial, showing functional gains in myotonic dystrophy type 1. The stock has fallen 37% in 3 months but is up 84% over 3 years. Analysts suggest it's 57% undervalued at $36 per share, citing its FORCE platform's efficiency. Risks include potential trial failures and equity dilution.
2 min readPosner Brian S purchased 2,500 shares of Dyne Therapeutics, Inc. (DYN) at $16.00 on 2026-10-02.
1 min readDyne Therapeutics, Inc. (DYN) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) - Data from a pooled dose group of participants initially enrolled in the multiple ascending dose (MAD) portion o
3 min readDyne Therapeutics (DYN) reported 12-month data from its Phase 1/2 ACHIEVE trial of z-basivarsen for Myotonic Dystrophy Type 1, showing functional improvements across multiple measures. The company expects topline data from the registrational expansion cohort in Q1 2027, with a potential U.S. Accelerated Approval submission in Q3 2027. The mean baseline vHOT in the ACHIEVE REC is 8.3 seconds.
2 min readDyne Therapeutics (DYN) shares fell after a recent rally driven by positive clinical data and a competitor's trial failure. Investors are taking profits, but the company's low debt and cash runway until 2028 provide financial flexibility. Risks include cash burn, no approved products, and dependence on future financing.
1 min readDyne Therapeutics (DYN) shares dropped 10% after-hours on plans to raise $300M via a stock offering. This follows FDA acceptance of its z-rostudirsen application for Duchenne muscular dystrophy, with a decision expected by January 2027. The company aims to use proceeds for clinical development and commercial infrastructure. DYN stock is up 22% year-to-date.
2 min readGlobal markets are mixed, with stocks and bonds falling as crude oil surges. The 10-year T-note yield rose to a 2.75-year high of 4.849%. Chipmakers and energy producers gained, while ServiceTitan (TTAN) fell over 30% after a larger-than-expected Q2 loss. Casys General Stores (CASY) dropped 14% due to a lower-than-expected Q1 gross margin. Meta Platforms (META) rose 6% on positive AI assistant reviews.
3 min readNovartis (NVS) shares fell 14% after a late-stage trial for del-desiran in myotonic dystrophy type 1 failed its primary test, marking its second trial failure in a week. The drug showed activity on secondary measures, and the company will review data. Dyne Therapeutics (DYN) and Sarepta Therapeutics (SRPT) also declined in sympathy.
2 min readDyne Therapeutics (DYN) stock fell 23% to $18.60 on Tuesday, despite plans to present one-year clinical data from its Phase 1/2 ACHIEVE trial for myotonic dystrophy type 1. The company will share six- and 12-month data from the trial and updated safety data at upcoming medical meetings. Dyne's 52-week range is $11.92 to $27.31.
2 min readDyne Therapeutics (DYN) shares fell 28% after Novartis' Phase III trial for a similar drug failed. Dyne's stock dropped to $17.50, reflecting investor concerns about its pipeline. The company has no revenue, and insiders have sold $168.4M in shares over 12 months. Dyne's GF Score is 34/100, indicating financial and operational challenges.
2 min read
